Cellares vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, automating end-to-end CAR-T and cell therapy production; raised $257M Series D in 2026 led by BlackRock and Eclipse;
About
Cellares is a clinical-stage biotech and contract manufacturing company founded in 2019 by Fabian Gerlinghaus, James Cha, and Yi Zhao, headquartered in South San Francisco, California. The company has built the world''s first fully automated, integrated cell therapy manufacturing platform — the Cell Shuttle — which automates the entire end-to-end process of manufacturing patient-specific T-cell therapies (including CAR-T cells) in a single closed system. Traditional cell therapy manufacturing is highly manual, requiring highly trained technicians, specialized cleanroom infrastructure, and weeks of labor-intensive processing. Cellares replaces this with industrial-scale automation, compressing production timelines and dramatically reducing the cost and variability of cell therapy manufacturing.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.